Texium/Smartsite with $239,020; OnGuard with $393,978; EquaShield with $435,473; and PhaSeal with $507,287. The acquisition cost difference between the most expensive system studied (PhaSeal), and the least expensive system (ChemoCLAVE) was calculated to be $307,005, a difference of 153.3 percent. In addition, the ChemoClave system was shown to generate 1,229 pounds less waste than the PhaSeal system, second only to the Texium/SmartSite system, which generated 214 pounds less waste annually than ChemoClave but cost nearly $40,000 more per year to implement.
"As economic pressures increase, procurement decisions can no longer rely solely on clinical efficacy studies that fail to also assess cost-effectiveness. Limiting waste volume generation to the lowest practical amount is also a major objective for facilities due to its toxicity and adverse implications to the environment," the researchers concluded. "In the absence of current, reliable comparative data on commercially available CSTDs, this evaluation of costs and waste may be used to guide organizations in the implementation of a CSTD."
In a March 2011 editorial in Journal of Oncology Pharmacy Practice, the authors concluded that "If, in fact, the different closed systems currently available are equally effective, then the choice comes down to cost and ease of use." In addition, the editorial urged hospitals to make sure that the CSTD they choose "is capable of containing the hazardous drug throughout all handling steps from reconstitution to administration."(1) To that end, a recent study comparing all commercially available CSTDs found that ChemoCLAVE provided significant cost savings to hospitals while scoring highest in terms of ease of use, practicality, and perceived safety by a cross-functional evaluation team of pharmacists, nurses, and value analysis professionals.(2)
In addition, as the world's only 100% needlefree system, ChemoClave completely and totally eliminates the risPage: 1 2 3 4 Related medicine technology :1
. Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 20112
. Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterologys 76th Annual Meeting3
. Groundbreaking Approach to Predicting Cancer Patients Response to Treatment Featured in Science Magazine4
. Ventana Medical Systems, Inc. Introduces Groundbreaking Laboratory Workflow Integration5
. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting6
. Pharmaceutical Industry Leaders to Tackle Groundbreaking Challenges, Opportunities for Pharma & Biotech at Elite Event7
. Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis8
. Groundbreaking Report Details the New $80 Billion Accountable-Care Market9
. International Dyslexia Association Announces Groundbreaking Parent Membership Initiative in Response to 40,000 Annual Inquiries10
. ERA-EDTA Congress 2011: Late Breaking Clinical Trials II11
. Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials